Our top pick for
Geron Corporation is a biotechnology business based in the US. Geron Corporation shares (GERN) are listed on the NASDAQ and all prices are listed in US Dollars. Geron Corporation employs 45 staff and has a trailing 12-month revenue of around USD$374,000.
|52-week range||USD$0.83 - USD$2.36|
|50-day moving average||USD$1.8535|
|200-day moving average||USD$1.8208|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.2|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-38,803,000|
|Return on assets TTM||-23.24%|
|Return on equity TTM||-42%|
|Market capitalisation||USD$541.8 million|
TTM: trailing 12 months
There are currently 36.4 million Geron Corporation shares held short by investors – that's known as Geron Corporation's "short interest". This figure is 1.6% down from 37.0 million last month.
There are a few different ways that this level of interest in shorting Geron Corporation shares can be evaluated.
Geron Corporation's "short interest ratio" (SIR) is the quantity of Geron Corporation shares currently shorted divided by the average quantity of Geron Corporation shares traded daily (recently around 4.2 million). Geron Corporation's SIR currently stands at 8.65. In other words for every 100,000 Geron Corporation shares traded daily on the market, roughly 8650 shares are currently held short.
However Geron Corporation's short interest can also be evaluated against the total number of Geron Corporation shares, or, against the total number of tradable Geron Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Geron Corporation's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Geron Corporation shares in existence, roughly 120 shares are currently held short) or 0.1178% of the tradable shares (for every 100,000 tradable Geron Corporation shares, roughly 118 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Geron Corporation.
Find out more about how you can short Geron Corporation stock.
We're not expecting Geron Corporation to pay a dividend over the next 12 months.
Geron Corporation's shares were split on a 1058:1000 basis on 22 July 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1058 shares. This wouldn't directly have changed the overall worth of your Geron Corporation shares – just the quantity. However, indirectly, the new 5.5% lower share price could have impacted the market appetite for Geron Corporation shares which in turn could have impacted Geron Corporation's share price.
Over the last 12 months, Geron Corporation's shares have ranged in value from as little as $0.83 up to $2.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Geron Corporation's is 1.2743. This would suggest that Geron Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.